A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.

Keiko Yamaoka,Shuichi Nagashima,Nobukazu Okada,Nagisa Sawayama,Shinsuke Saito,Manabu Takahashi,Kenta Okada,Kazuhiro Endo,Masaru Koizumi,Hideki Sasanuma,Ken Ebihara,Atsuko Kasajima,Noriyoshi Fukushima,Naohiro Sata,Shun Ishibashi

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.

2021

Keiko Yamaoka
Shuichi Nagashima
Nobukazu Okada
Nagisa Sawayama
Shinsuke Saito
Manabu Takahashi
Kenta Okada
Kazuhiro Endo
Masaru Koizumi
Hideki Sasanuma
Ken Ebihara
Atsuko Kasajima
Noriyoshi Fukushima
Naohiro Sata
Shun Ishibashi

Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations